In recent phase 2 trials Coleys ProMune , in combination with 2 chemos , achieved a 42% objective response against NSCLC compared to the 2 chemos alone seeing a 24% response . Rational Therapeutics research suggests Coramsine can beat the 42% as a single agent and the only NSCLC patient in Coramsines trial has done nothing to disprove that , showing a strong response of over 50% tumour reduction .
SBP Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
